This international website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
|
BRAFTOVI▼ (encorafenib) |
|
BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. BRAFTOVI+MEKTOVI Melanoma - Product website (These websites are dedicated to European Healthcare Professionals only) |
| JAVLOR (vinflunine) |
|
JAVLOR (vinflunine) is an antineoplasic agent indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status >=2. See EU Product Information |
|
MEKTOVI▼ (binimetinib) |
|
MEKTOVI (binimetinib) is a proteine kinase inhibitor indicated in combination with BRAFTOVI (encorafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. BRAFTOVI+MEKTOVI Melanoma - Product website (This website is dedicated to European Healthcare Professionals only) |
| NAVELBINE IV (vinorelbine) |
|
NAVELBINE IV (vinorelbine) is an antineoplasic agent indicated for the treatment of Advanced Breast Cancer and Non-Small Cell Lung Cancer. |
| NAVELBINE Oral (vinorelbine) |
|
NAVELBINE oral (vinorelbine) is an antineoplasic agent indicated for the treatment of Advanced Breast Cancer and Non-Small Cell Lung Cancer. |
|
NERLYNX▼ (neratinib) |
|
NERLYNX (neratinib) is an oral pan-HER irreversible tyrosine kinase inhibitor, indicated in the European Union for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. In China, NERLYNX is indicated as extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer, to follow adjuvant trastuzumab-based therapy. See EU Product Information NERLYNX Product website (This website is dedicated to European Healthcare Professionals only) |
|
EBVALLO▼ (tabelecleucel) |
|
EBVALLO is an allogeneic EBV-specific T-cell immunotherapy indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. EBVALLO Product website ( This website is dedicated to European Healthcare Professionals only) |
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.